Bamungen Laboratories Co., Ltd was founded on June 08, 2018 and is located in the Biomedical Park of Zhubei City, Hsinchu County, Taiwan, ROC.

Bamungen is a company that specializes in development and sale recombinant proteins (mostly are vaccine antigens). 

We use bacterial (E. coli) expression system to produce affordable recombinant proteins and sell them to diagnostics and vaccine companies to develop their products.

The mission of Bamungen Labs is to research and develop therapeutic vaccines and diagnostic kits for human chronic diseases to improve human life with biotechnology. 

At present, the main business items of Bamungen Labs are development and sell recombinant proteins. In addition to develop vaccine antigens for human chronic disease, Bamungen develop vaccine antigens for animals as well, These recombinant vaccine antigens have a special structure and can be used orally to induce systemic immune responses to prevent pathogenic infections. And these vaccine antigens can be used to produce specific antibodies for diagnostic uses.

Bamugen's oral vaccine antigens for human chronic diseases:

Non-communicable chronic diseases, such as dementia, cancer, diabetes or cardiovascular diseases, are beginning to dominate the global health landscape. The occurrence of many chronic diseases is caused by excessive production of some proteins (peptides) in the body.

These proteins are therapeutic targets. Medicines against therapeutic targets have been developed from small molecules to advanced monoclonal antibodies (mAb). Although mAbs have made treatments more effective and less side effects, they are expensive causing many people cannot afford them. We believe that vaccines can reduce the activities of therapeutic targets in vivo by active immunization, the treatment effects will be like mAbs but the medication cost will be much less.

Monoclonal Antibodies Vaccines of Bamungen
Production method Tissue cultures E.coli fermentation
Production cost Cost of culture medium (>NT$1,000/L) Cost of culture medium (<NT$20/L)
(protein may need refolding)
Developing time long short
Dose Mostly by injection (dose: mg/kg) Oral delivery (dose: ug/kg)
Cost of therapy > NT$ 1 million/yr (Estimate: < NT$ 50 thousands/yr)
Effect Instantly
(can be used to treat acute sickness)
Delay for about 2 weeks to produce enough antibodies
(can be used for chronic disease treatment or for prophylaxis)

Bamungen's oral vaccines:

Self-proteins generally do not induce antibody responses, because the animal immune system has evolved a set of mechanisms to avoid autoimmune reactions. However, the current molecular biology technology has methods to induce the production of antibodies against self antigens: for example, the use of antigen fusion with powerful exogenous T-cell epitope, or antigen conjugated with exogenous carrier molecules to achieve good results.

For a strong B cell response, two signals are required: activation of B cell by corss- linking of B cell receptors (BCRs) and stimulation of antigen-specific T helper (Th) cells. When use self-antigen covalently linked to exogenous carrier molecules to immune animals. If the self-antigen can make cross-linking of BCRs, the B cells with cross-linked BCRs will express specific antibodies by aid of carrier specific T cells. In addition to providing T cell epitopes, appropriate carrier proteins can also assist antigens to enter the body through mucosa (oral mucosa, nasal mucosa, etc.) to trigger a systemic immune response

Although some therapeutic target proteins will mask or change part of the structures due to protein glycosylation, the linear B cell epitopes in the non-glycosylated region will still be recognized by the antibody, The bindings of target protien by antibodies, which are induced by our antigenic fusion proteins based on B cell epitopes (a small peptide consists of 6-16 amino acids) will not be affected by protein glycosylation. This is the reason why Bamungen Labs can produce various effective vaccine antigens by using efficient and low-cost E. coli system rather than expensive cell culture technologies and equipments.

We designed multiple B-cell epitope on the immunogen protein to induce cross-linking of B-cell receptors (BCR), thus activating B-cells, leading to the production of a large amount of antibodies.